Hemoglobinopathy Nursing Program and Pediatric Nursing Students
May 21, 2022 updated by: Ahmed Loutfy, Beni-Suef University
Effect of a Hemoglobinopathy Nursing Program on Pediatric Student Nurses' Awareness and Performance
Hemoglobinopathies are the most common life threatening, monogenic disorders in the world.
The most common causes of hemoglobinopathies are sickle cell disease and thalassemia.
Aim: This study aimed to evaluate the effect of a hemoglobinopathy nursing program on pediatric nursing students' performance.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
108
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Other
-
Banhā, Other, Egypt, 13511
- Benha University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 22 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- pediatric nursing students registered for the academic year 2016/2017
Exclusion Criteria:
- Any student had personal or family history of hemoglobinopathies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 1
Experimental Group (n=54) The implementation phase was achieved through sessions within Feb-April2017 second semester of the academic year 2016/2017.Each session started by the objectives of the new session and summary of previous one.
Motivation and reinforcement during session were used to enhance participation and sharing in this study.
The researcher did the explanation of the questionnaire sheet to the pediatric student nurses to assess their awareness and attitude toward hemoglobinopathies.
The researcher observed the pediatric student nurses 'practice during applying blood transfusion, subcutaneous medication administration, and oral medication administration using the observational checklist at faculty laboratory.
|
"Hemoglobinopathy Nursing Program" is more informative for "Groupe 1" than "Group 2"
|
|
No Intervention: Group 2
Control Group (n=54) The researcher did the explanation of the questionnaire sheet to the pediatric student nurses to assess their awareness and attitude toward hemoglobinopathies.
The researcher observed the pediatric student nurses 'practice during applying blood transfusion, subcutaneous medication administration, and oral medication administration using the observational checklist at faculty laboratory.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pediatric nursing students' awareness
Time Frame: 10 weeks
|
Measure Students' awareness through: 01. Personal Data and PNSs' Awareness Questionnaire -sixty (60) questions. A score of (one) for correct answers, and (zero) for the wrong answers. The total scores ranged from (0-60 mark). |
10 weeks
|
|
Pediatric nursing students' Attitude
Time Frame: 10 weeks
|
Pediatric nursing students' Attitude Scale - nine (9) questions. A five-point Likert scale by give a score of (four) for Strongly Agree, (three) for Agree, (two) for Undecided, (one) for Disagree and (zero) for Strongly Disagree. The total score ranged from (0-36 mark). |
10 weeks
|
|
Pediatric nursing students' Practice
Time Frame: 10 weeks
|
Observational Checklists - forty (40) items.
A score of (two) for completely done, (one) for incompletely done and (zero) for not done.
The total score ranged from (0-80 mark), scores less than 60% were considered incompetent practice.
|
10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 27, 2017
Primary Completion (Actual)
April 26, 2017
Study Completion (Actual)
May 11, 2017
Study Registration Dates
First Submitted
May 12, 2022
First Submitted That Met QC Criteria
May 21, 2022
First Posted (Actual)
May 25, 2022
Study Record Updates
Last Update Posted (Actual)
May 25, 2022
Last Update Submitted That Met QC Criteria
May 21, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PediaMarch201601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
The study approval in March 2016, it's my doctorate dissertation and I will upload Results Reporting and IPD file as per request.
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months.
Extensions will be considered on a case-by-case basis.
IPD Sharing Access Criteria
""Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP).
For more information or to submit a request, please contact ahmed.loutfy@nursing.bsu.edu.eg"
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.